Abstract
The uptake and utilization of glucose and glutamine by cancer cells are markedly higher than by most nontransformed, normal epithelial and mesenchymal cells. This metabolic shift enables the production of ATP and anabolic precursors necessary for the synthesis of proteins, lipids and nucleotides required for survival, proliferation and invasiveness. The observations that certain oncogenic proteins (Ras, c-Myc and HIF-1) and tumor suppressors (p53, PTEN, Rb and VHL) regulate the expression and activity of several metabolic enzymes have supported their potential as molecular targets for the development of anti-neoplastic agents. Indeed, recent pre-clinical studies have shown that several established and novel inhibitors of metabolic enzymes exhibit reasonable therapeutic indices when tested in xenograft models of tumorigenesis. In this review, we will discuss the rationale of targeting metabolic enzymes for the treatment of cancer and then will describe published pre-clinical and clinical data for several inhibitors of metabolism in cancer.
Keywords: Glycolysis, chemotherapy, glucose.
Current Enzyme Inhibition
Title:Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Volume: 9 Issue: 2
Author(s): Julie O’Neal and Jason Chesney
Affiliation:
Keywords: Glycolysis, chemotherapy, glucose.
Abstract: The uptake and utilization of glucose and glutamine by cancer cells are markedly higher than by most nontransformed, normal epithelial and mesenchymal cells. This metabolic shift enables the production of ATP and anabolic precursors necessary for the synthesis of proteins, lipids and nucleotides required for survival, proliferation and invasiveness. The observations that certain oncogenic proteins (Ras, c-Myc and HIF-1) and tumor suppressors (p53, PTEN, Rb and VHL) regulate the expression and activity of several metabolic enzymes have supported their potential as molecular targets for the development of anti-neoplastic agents. Indeed, recent pre-clinical studies have shown that several established and novel inhibitors of metabolic enzymes exhibit reasonable therapeutic indices when tested in xenograft models of tumorigenesis. In this review, we will discuss the rationale of targeting metabolic enzymes for the treatment of cancer and then will describe published pre-clinical and clinical data for several inhibitors of metabolism in cancer.
Export Options
About this article
Cite this article as:
O’Neal Julie and Chesney Jason, Targeting Metabolic Enzymes in Cancer – Clinical Trials Update, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020007
DOI https://dx.doi.org/10.2174/1573408011309020007 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](https://www.eurekaselect.com/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Total Polyphenols and Bioactivity of Seeds and Sprouts in Several Legumes
Current Pharmaceutical Design History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Apolipoprotein A-I/HDL Infusion Therapy for Plaque Stabilization-Regression: A Novel Therapeutic Approach
Current Pharmaceutical Design Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Curative Effects of <i>Dhatryadi ghrita</i> Bioactive Extracts on Ethanol Withdrawal Syndrome in Wistar Rats
Current Bioactive Compounds Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Current Drug Targets Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Transient Secondary Hypothyroidism and Thyroid Hormone Replacement Therapy in Pediatric Postoperative Cardiopulmonary Bypass
Current Cardiology Reviews Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design